株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

喘息:パイプライン製品の分析

Asthma - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232777
出版日 ページ情報 英文 592 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.09円で換算しております。
Back to Top
喘息:パイプライン製品の分析 Asthma - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 592 Pages
概要

喘息は、気道が炎症によって狭くなる慢性疾患です。喘息の症状としては、息切れ、胸苦しさや痛み、慢性的な咳などがあり、その原因としては、喘息にかかりやすい家系、過体重、喫煙、排ガスやその他の大気汚染物質にさらされることなどが挙げられます。喘息の代表的な治療薬としては、吸入コルチコステロイド薬、ロイコトリエン拮抗薬、抗ヒスタミン剤、充血除去剤などがあります。

当レポートでは、喘息治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

喘息の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

目次
Product Code: GMDHC10370IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H1 2018, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 40, 27, 1, 112, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 8
  • Asthma - Overview 9
  • Asthma - Therapeutics Development 10
  • Asthma - Therapeutics Assessment 37
  • Asthma - Companies Involved in Therapeutics Development 55
  • Asthma - Drug Profiles 108
  • Asthma - Dormant Projects 524
  • Asthma - Discontinued Products 549
  • Asthma - Product Development Milestones 555
  • Appendix 566

List of Tables

  • Table 1: Number of Products under Development for Asthma, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 10: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 11: Products under Development by Companies, H1 2018
  • Table 12: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 13: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 14: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 15: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 16: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 17: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 18: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 19: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 20: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 21: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 22: Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Table 23: Products under Development by Universities/Institutes, H1 2018
  • Table 24: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Table 25: Number of Products by Stage and Target, H1 2018
  • Table 26: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 27: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Table 28: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Table 29: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
  • Table 30: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
  • Table 31: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 32: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 33: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Table 34: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Table 35: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
  • Table 36: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
  • Table 37: Number of Products by Stage and Route of Administration, H1 2018
  • Table 38: Number of Products by Stage and Molecule Type, H1 2018
  • Table 39: Asthma - Pipeline by 4D Pharma PLC, H1 2018
  • Table 40: Asthma - Pipeline by AB Science SA, H1 2018
  • Table 41: Asthma - Pipeline by AbbVie Inc, H1 2018
  • Table 42: Asthma - Pipeline by Abeome Corp, H1 2018
  • Table 43: Asthma - Pipeline by Accolade Pharmaceuticals LLC, H1 2018
  • Table 44: Asthma - Pipeline by Adamis Pharmaceuticals Corp, H1 2018
  • Table 45: Asthma - Pipeline by ALK-Abello AS, H1 2018
  • Table 46: Asthma - Pipeline by Allergan Plc, H1 2018
  • Table 47: Asthma - Pipeline by Allergopharma GmbH & Co KG, H1 2018
  • Table 48: Asthma - Pipeline by Almirall SA, H1 2018
  • Table 49: Asthma - Pipeline by Amgen Inc, H1 2018
  • Table 50: Asthma - Pipeline by Amphastar Pharmaceuticals Inc, H1 2018
  • Table 51: Asthma - Pipeline by AnaptysBio Inc, H1 2018
  • Table 52: Asthma - Pipeline by AnGes Inc, H1 2018
  • Table 53: Asthma - Pipeline by Antisense Therapeutics Ltd, H1 2018
  • Table 54: Asthma - Pipeline by Apollo Endosurgery Inc, H1 2018
  • Table 55: Asthma - Pipeline by ARA Healthcare Pvt Ltd, H1 2018
  • Table 56: Asthma - Pipeline by ASIT Biotech SA, H1 2018
  • Table 57: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
  • Table 58: Asthma - Pipeline by Astellas Pharma Inc, H1 2018
  • Table 59: Asthma - Pipeline by AstraZeneca Plc, H1 2018
  • Table 60: Asthma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Table 61: Asthma - Pipeline by Biotec Pharmacon ASA, H1 2018
  • Table 62: Asthma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Table 63: Asthma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
  • Table 64: Asthma - Pipeline by Celon Pharma SA, H1 2018
  • Table 65: Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2018
  • Table 66: Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2018
  • Table 67: Asthma - Pipeline by Cognosci Inc, H1 2018
  • Table 68: Asthma - Pipeline by Crossject SA, H1 2018
  • Table 69: Asthma - Pipeline by CrystalGenomics Inc, H1 2018
  • Table 70: Asthma - Pipeline by CSL Ltd, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Asthma, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top